2017
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Abstract: Over the past decade, major advances have been made in the management of advanced non-small cell lung cancer (NSCLC). There has been a particular focus on the identification and targeting of putative driver aberrations, which has propelled NSCLC to the forefront of precision medicine. Several novel molecularly targeted agents have now achieved regulatory approval, while many others are currently in late-phase clinical trial testing. These antitumor therapies have significantly impacted the clinical outcomes of…
Search citation statements
Paper Sections
Select...
14
5
4
0
Citation Types
0
17
0
1
Year Published
2017
2025
Publication Types
Select...
19
2
1
Relationship
3
19
Authors
Journals
Cited by 22 publications
(18 citation statements)
References 126 publications
0
17
0
1
“…the neoadjuvant approach also paves the route for the design of clinical trials incorporating novel agents to allow for quicker in vivo and early read out of efficacy. Compared to breast cancer and lung cancer, which have had a rapid increase in survival due to the identification of novel targets and pathways, colon cancer treatment has significantly lagged behind in the field of precision oncology (40,41).…”
Section: Discussionmentioning
confidence: 99%
“…the neoadjuvant approach also paves the route for the design of clinical trials incorporating novel agents to allow for quicker in vivo and early read out of efficacy. Compared to breast cancer and lung cancer, which have had a rapid increase in survival due to the identification of novel targets and pathways, colon cancer treatment has significantly lagged behind in the field of precision oncology (40,41).…”
Section: Discussionmentioning
confidence: 99%
“…The molecular diagnosis of mutations in EGFR exons 18, 19, 20 and 21 is recommended in all patients with advanced NSCLC, since TKI therapy provides significant improvement in survival and quality of life. 4 5 Most NSCLCs are diagnosed at an advanced disease stage, when surgery is not an option. Therefore, in more than 85% of cases, the clinical management of patients with NSCLC must rely on diagnostic procedures carried out on tissue samples obtained through minimally invasive procedures, that is, small biopsies or cytology sampling.…”
Section: Discussionmentioning
confidence: 99%
“…Yes-associated protein (Yap) is a 65 kDa proline-rich phosphoprotein, which is located at locus 11q22 ( 48 ). A previous study reported that YAP may have oncogenic functions, and elevated YAP expression is associated with malignant tumors ( 21 , 49 ). In the present study, we found that Yap expression is increased in gastric cancer when compared to that noted in normal gastric mucosal cells.…”
Section: Discussionmentioning
confidence: 99%
